SCHEMBL3022765

SCHEMBL3022765

Cc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4)CC3)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.42
SMN1; SMN2 Q16637 6/20 0.41
ALDH1A1 P00352 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MAPK1 P28482 3/20 0.39
GPR6 P46095 2/20 0.39
HTR2A P28223 2/20 0.39
HTR2C P28335 2/20 0.39
KCNH2 Q12809 2/20 0.39
ALOX5 P09917 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MAPT P10636 4/20 0.38
HTT P42858 3/20 0.38
KMT2A Q03164 2/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017469 0.95 GBA1 (0.45) GBA1SMN1; SMN2ALDH1A1HTR2ANPC1
SCHEMBL3010872 0.92 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1L3MBTL1MAPK1GPR6
SCHEMBL3013102 0.91 GBA1 (0.41) GBA1SMN1; SMN2ALDH1A1L3MBTL1MAPK1
SCHEMBL3019220 0.91 SMN1; SMN2 (0.40) GBA1SMN1; SMN2ALDH1A1L3MBTL1MAPK1
SCHEMBL3017967 0.91 GBA1 (0.42) GBA1SMN1; SMN2ALDH1A1MAPK1NPC1
SCHEMBL3017562 0.90 SMN1; SMN2 (0.39) SMN1; SMN2ALDH1A1L3MBTL1MAPK1GPR6
SCHEMBL3021897 0.90 HTR2A (0.45) SMN1; SMN2ALDH1A1L3MBTL1MAPK1GPR6
SCHEMBL3001231 0.90 MAPT (0.42) GBA1SMN1; SMN2ALDH1A1MAPK1HTR2A
SCHEMBL3011260 0.90 MAPT (0.42) GBA1SMN1; SMN2ALDH1A1MAPK1HTR2A
SCHEMBL3015039 0.90 GBA1 (0.42) GBA1SMN1; SMN2ALDH1A1HTR2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GBA1 4/4885SMN1; SMN2 1/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.